Source: Eur Respir J 2012; 39: 1263-1266
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Fattorini Lanfranco, Migliori Giovanni Battista, Cassone Antonio, Mustazzolu Alessandro, Piccaro Giovanni, Filippini Perla, Cirillo Daniela Maria, Borroni Emanuele, the Italian Multicentre Study on Resistance to Antituberculosis Drugs (SMIRA) Group. Proficiency testing of first- and second-line anti-tuberculosis drugs in Italy. Eur Respir J 2012; 39: 1263-1266

Member's Comments

No comment yet.

Related content which might interest you: Novel drug regimens against MDR-TB Source: International Congress 2016 – The problem of multidrug-resistant tuberculosis Year: 2016 Resistance to second-line anti-tuberculosis drugs: new drug resistant TB treatment problem Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007 Resistance to second-line antituberculous drugs of Mtb strains in TB institute clinic Source: Eur Respir J 2007; 30: Suppl. 51, 442s Year: 2007 Bacteriological conversion in XDR-TB and RR-TB patients with fluoroquinolone resistance treated with and without new and repurposed anti-TB drugs in Azerbaijan prisons Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Availability of anti-tuberculosis drugs in Europe Source: Eur Respir J 2012; 40: 500-503 Year: 2012 New anti-tuberculosis drugs and regimens: 2015 update Source: ERJ Open Res 2015; 1: 00010-2015 Year: 2015 Availability of PCR for second-line drugs in Europe Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment Year: 2016 Application of next-generation sequencing to detect MTB resistance to first- and second-line anti-TB drugs Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Availability of fixed-dose, child-friendly formulations of first-line tuberculosis drugs in Europe Source: Eur Respir J, 58 (3) 2101196; 10.1183/13993003.01196-2021 Year: 2021 Availability of drug susceptibility testing to new/re-purposed anti-tuberculosis drugs: a TBnet study Source: Virtual Congress 2021 – Advances in the diagnosis of tuberculosis, multidrug-resistant tuberculosis and nontuberculous mycobacterial disease Year: 2021 Anti-tuberculosis drugs Source: International Congress 2017 – State of the art session: "Respiratory infections" Year: 2017 Resistance rates of Mycobacterium tuberculosis to first-line antituberculosis drugs. Trends in Greece during the period 1991–2000 Source: Eur Respir J 2003; 22: Suppl. 45, 525s Year: 2003 Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes Source: Eur Respir J 2013; 42: 156-168 Year: 2013 Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020 First-line anti-TB drug resistance pattern and its trend in the national TB referral center in Iran Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III Year: 2008 Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006 Efficacy of intravenous administration of anti-tuberculosis drugs in patients with multidrug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Pre-chemotherapy drug sensitivity test for antitubercular drugs in India – is it essential? Source: Eur Respir J 2005; 26: Suppl. 49, 649s Year: 2005 Second-line anti-tuberculosis drug concentrations for susceptibility testing in the MODS assay Source: Eur Respir J 2013; 41: 1163-1171 Year: 2013